Becton, Dickinson Boosts FY23 Outlook - Update

RTTNews | Před 824 dny
Stocktwits
Becton, Dickinson Boosts FY23 Outlook - Update

(RTTNews) - While reporting financial results for the second quarter on Thursday, medical technology company Becton, Dickinson and Co. (BDX) raised its adjusted earnings and revenue outlook for fiscal 2023.

For fiscal 2023, the company now projects adjusted earnings in a range of $12.10 to $12.32 per share on revenues between approximately $19.2 billion to $19.3 billion, with currency-neutral revenue growth of 6.5 to 7.0 percent.

Previously, the company expected adjusted earnings in a range of $12.07 to $12.32 per share on revenues between approximately $19.1 billion to $19.3 billion, with currency-neutral revenue growth of 5.75 to 6.75 percent.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $12.21 per share on revenue growth of 1.9 percent to $19.22 billion for the year. Analysts' estimates typically exclude special items.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

Značky : BDX
Stocktwits
read more
BD Recalls ChloraPrep Clear 1 ML Applicators

BD Recalls ChloraPrep Clear 1 ML Applicators

Medical technology company Becton, Dickinson and Co. or BD has recalled one lot of ChloraPrep Clear 1 mL Applicators citing potential fungal contamination, the U.S. Food and Drug Administration said. Under certain environmental conditions, the contamination allows the growth of Aspergillus penicillioides within the packaging.
RTTNews | Před 167 dny
Becton, Dickinson Boosts FY24 Ad, EPS Outlook - Update

Becton, Dickinson Boosts FY24 Ad, EPS Outlook - Update

While reporting financial results for the third quarter on Thursday, medical technology company Becton, Dickinson and Co. (BDX) raised its adjusted earnings guidance for fiscal 2024, while trimming annual revenue outlook.
RTTNews | Před 369 dny
BD Announces Global Commercial Release Of New BD FACSDiscover S8 Cell Sorters

BD Announces Global Commercial Release Of New BD FACSDiscover S8 Cell Sorters

Medical technology company BD or Becton, Dickinson and Co. (BDX) announced Friday the global commercial release of new cell sorters that will enable more researchers in a broader range of fields, including cell biology, cancer research and immunology, to reveal insights that were previously invisible in traditional flow cytometry experiments.
RTTNews | Před 487 dny
BD Gets FDA 510(k) Clearance For Fingertip Blood Collection Device

BD Gets FDA 510(k) Clearance For Fingertip Blood Collection Device

Medical technology company Becton, Dickinson and Co. or BD (BDX) announced Thursday it has received 510(k) clearances from the U.S. Federal Drug Administration (FDA) for a novel blood collection device that obtains blood samples from a fingerstick that produce lab-quality results for some of the most commonly ordered blood tests.
RTTNews | Před 607 dny
Becton, Dickinson Boosts FY23 Outlook - Update

Becton, Dickinson Boosts FY23 Outlook - Update

While reporting financial results for the first quarter on Thursday, medical technology company Becton, Dickinson and Co. or BD (BDX) raised its adjusted earnings and revenue outlook for fiscal 2023.
RTTNews | Před 915 dny
U.S. Service Sector Growth Unexpectedly Slows In July

U.S. Service Sector Growth Unexpectedly Slows In July

A report released by the Institute for Supply Management on Tuesday unexpectedly showed a modest slowdown in the pace of growth by U.S. service sector activity in the month of July. The ISM said its services PMI edged down to 50.1 in July from 50.8 in June. While a reading above 50 still indicates growth, economists had expected the index to rise to 51.5.
RTTNews | Před 36 minutami
Nástroje
Ekonomický kalendář
Otevírací hodiny trhu
Úrokové sazby
Kalendář svátků
Forexový trh
Forex volatilita
Korelace Forexu
Novinky na Forexu
forex analysis
COT údaje
Likvidita
Forex kalkulačky
Forex Tepelná mapa
Tepelná mapa indikátorů
Komunita
Komunita
Systémy
Nejpopulárnější systémy
Strategie
Soutěže
Forexové grafy
Forexový sentiment
Indikátor Outlook
Recenze
Brokeři
Prop Trading Firms
Služby VPS
Poskytovatelé signálu
Služby programování EA
Affiliate Programs
Služby PAMM Brokera
Služby slevového programu
Obchodní platformy
Odborní poradci
Kryptoburzy
Kurzy obchodování
Brokeři
Forex Spready
Nabídky Forex brokerů
Swapy Forex brokerů
Objem brokera Forexu
Propagační akce Forex Brokera Tisková Zpráva
Platforma
Miniaplikace
Funkce
API
RSS
Stock Portfolio
Affiliate Software
Rozšířené grafy
Podpora
Časté dotazy
Pomoc
Kontaktuj nás
Nahlásit chybu!
O
Blog
& copy; 2025 Myfxbook Ltd. Všechna práva vyhrazena.
UPOZORNĚNÍ NA VYSOKÉ RIZIKO: Obchodování s devizami přináší vysokou úroveň rizika, které nemusí být vhodné pro všechny investory. Páka vytváří další rizika a ztráty. Než se rozhodnete obchodovat s devizami, důkladně zvažte své investiční cíle, úroveň zkušeností a toleranci vůči riziku. Můžete přijít o část nebo všechny své počáteční investice. Neinvestujte peníze, které si nemůžete dovolit ztratit. Educate yourself on the risks associated with foreign exchange trading, and seek advice from an independent financial or tax advisor if you have any questions. Všechny údaje a informace jsou poskytovány "tak, jak jsou". pouze pro informační účely a nejsou určeny pro obchodní účely nebo rady. Výkonnost v minulosti neznamená výkonnost v budoucnosti.